ClinicalTrials.gg
CompletedNCT02605395Updated Oct 1, 2018Results posted

Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions

A Phase 4 interventional study of IDIAZOLE 20mg DR tabs and PARIET 20 mg DR tabs in Gastrointestinal Diseases, sponsored by GlaxoSmithKline. Completed at 1 site in Egypt. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-01.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Other

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Mar 2014, registered May 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is an open-label, randomized, single dose, two-sequence, two-periods crossover study, separated by 7 days washout interval from the first Study Drug Administration. This study is conducted to determine the bioequivalence of Rabeprazole from IDIAZOLE 20mg Delayed-Release (DR) tablets (tabs) and PARIET 20 mg DR tabs after a single oral dose administration of each to healthy adults fed under conditions.

In Period 1, subjects will be randomized to either Idiazole 20mg DR tabs or PARIET 20 mg DR tabs. Following a washout of at least 7 days, subjects will be crossed over in Period 2 to receive the treatment that they did not receive in Period 1.

PARIET is a registered trademark of EISAI Co. Limited.

02

Conditions studied

  • Gastrointestinal Diseases

Keywords

  • Bioequivalence
  • Fed condition
  • PARIET 20 mg
  • IDIAZOLE 20mg
  • Rabeprazole
03

In context

Gastrointestinal Diseases

549 studies on the registry are indexed under Gastrointestinal Diseases; 102 are open to participants now.

This study's enrollment of 70 is below the median of 80 across 388 interventional studies indexed under Gastrointestinal Diseases.

Browse Gastrointestinal Diseases studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female, age 18 to 55 years, inclusive.
  • Body weight within 10 percent of normal range according to the accepted normal values for (BMI).
  • Medical demographics without evidence of deviation from normal medical condition.
  • Results of clinical laboratory test are within the normal range or with a deviation that is not considered clinically significant by principal investigator.
  • Subject does not have allergy to the drugs under investigation.

Exclusion criteria

Exclusion Criteria:

  • Subjects with known allergy to the products tested.
  • Subjects whose values of were outside the accepted normal ranges.
  • Female subjects who were pregnant, nursing or taking pills.
  • Medical demographics with evidence of deviation from normal medical condition.
  • Results of laboratory tests which are clinically significant.
  • Acute infection within one week preceding first study drug administration.
  • History of drug or alcohol abuse.
  • Subject does not agree not to take any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study.
  • Subject is on a special diet (for example subject is vegetarian).
  • Subject does not agree not to consume any beverages or foods containing methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to the study administration of either study period until donating the last sample in each respective period.
  • Subject does not agree not to consume any beverages or foods containing grapefruit 7 days prior to first study drug administration until the end of the study.
  • Subject has a history of severe diseases which have direct impact on the study.
  • Participation in a bioequivalence study or in a clinical study within the last 6 weeks before first study drug administration.
  • Subject intends to be hospitalized within 6 weeks after first study drug administration.
  • Subjects who, through completion of this study, would have donated more than 500 milliliter (mL) of blood in 7 days, or 750 mL of blood in 30 days, 1000 mL in 90 days, 1250 mL in 120 days, 1500 ml in 180 days, 2000 mL in 270 days, 2500 mL of blood in 1 year.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Group A-Idiazole then Pariet

    Subjects will receive a single oral dose of IDIAZOLE 20mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fed condition in treatment period 2.

    Drug: IDIAZOLE 20mg DR tabs · Drug: PARIET 20 mg DR tabs

  • Experimental
    Group B-Pariet then Idiazole

    Subjects will receive a single oral dose of PARIET 20 mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of Idiazole 20mg DR tabs under fed condition in treatment period 2.

    Drug: IDIAZOLE 20mg DR tabs · Drug: PARIET 20 mg DR tabs

Interventions

  • IDIAZOLE 20mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.

  • PARIET 20 mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg rabeprazole sodium.

06

What researchers measure

Primary outcomes

  1. Maximal Measured Plasma Concentration (Cmax) of Rabeprazole

    Blood samples were collected for pharmacokinetic analyses in each period at specified time points. Pharmacokinetic parameters of rabeprazole were estimated using standard non-compartmental methods. The Cmax was computed directly from measured data.

    Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2

  2. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC [0-t]) of Rabeprazole

    Blood samples were collected for pharmacokinetic analyses in each period at specified time points. Pharmacokinetic parameters of rabeprazole were estimated using standard non-compartmental methods. AUC (0-t) was calculated from measured data points from time of administration to time of last quantifiable concentration (Clast) by the linear trapezoidal rule.

    Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2

  3. Mean Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC [0 to Infinity]) of Rabeprazole

    Blood samples were collected for pharmacokinetic analyses in each period at specified time points. Pharmacokinetic parameters of rabeprazole were estimated using standard non-compartmental methods.

    Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2

Secondary outcomes

  1. Mean Time to the Maximum Plasma Concentration (Tmax) of Rabeprazole

    Blood samples were collected for pharmacokinetic analysis in each period at specified time points. Pharmacokinetic parameters of Rabeprazole were estimated using standard non-compartmental methods. Tmax was computed directly from the measured data.

    Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2

  2. Mean Apparent First-order Elimination or Terminal Rate Constant (Ke) of Rabeprazole

    Blood samples were collected for pharmacokinetic analysis in each period at specified time points. Pharmacokinetic parameters of Rabeprazole were estimated using standard non-compartmental methods. Ke was derived from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations.

    Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2

  3. Mean Terminal Half Life (t1/2) of Rabeprazole

    Half life is the period of time required for the concentration or amount of drug in the body to be reduced by one-half. Blood samples were collected for pharmacokinetic analysis in each period at specified time points. Pharmacokinetic parameters of Rabeprazole were estimated using standard non-compartmental methods. t1/2 was calculated as: t1/2 = Ln(2) / (-b), where b was obtained as the slope of the linear regression of the Ln-transformed plasma concentrations versus time in the terminal period of the plasma curve.

    Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2

07

Results

Posted Oct 1, 2018

Participant flow

Bioequivalence of rabeprazole from Idiazole 20 milligram (mg) tablets and Pariet 20 mg tablets was investigated after single oral dose administration to healthy participants under fed conditions. This study was conducted from 22 March 2014 to 30 March 2014.

Period 1, Day 1
Participant flow — Period 1, Day 1
MilestonePariet 20 mg Followed by Idiazole 20 mgIdiazole 20 mg Followed by Pariet 20 mg
Started3535
Completed3535
Not completed00
Washout Period, Day 2 to Day 7
Participant flow — Washout Period, Day 2 to Day 7
MilestonePariet 20 mg Followed by Idiazole 20 mgIdiazole 20 mg Followed by Pariet 20 mg
Started3535
Completed3535
Not completed00
Period 2, Day 8
Participant flow — Period 2, Day 8
MilestonePariet 20 mg Followed by Idiazole 20 mgIdiazole 20 mg Followed by Pariet 20 mg
Started3535
Completed3535
Not completed00

Outcome measures

PrimaryMaximal Measured Plasma Concentration (Cmax) of Rabeprazole

Blood samples were collected for pharmacokinetic analyses in each period at specified time points. Pharmacokinetic parameters of rabeprazole were estimated using standard non-compartmental methods. The Cmax was computed directly from measured data.

Time frame:
Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2
Reported as:
Mean · Nanograms per milliliter
Maximal Measured Plasma Concentration (Cmax) of Rabeprazole
Nanograms per milliliterIdiazole 20 mgPariet 20 mg
Maximal Measured Plasma Concentration (Cmax) of Rabeprazole393.50 ± 158.60415.83 ± 179.24
Statistical analysis
  • Idiazole 20 mg vs Pariet 20 mg · Ratio of means: 95.71 · 90% CI 90.12 to 101.65
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC [0-t]) of Rabeprazole

Blood samples were collected for pharmacokinetic analyses in each period at specified time points. Pharmacokinetic parameters of rabeprazole were estimated using standard non-compartmental methods. AUC (0-t) was calculated from measured data points from time of administration to time of last quantifiable concentration (Clast) by the linear trapezoidal rule.

Time frame:
Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2
Reported as:
Mean · Hour*nanograms per milliliter
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC [0-t]) of Rabeprazole
Hour*nanograms per milliliterIdiazole 20 mgPariet 20 mg
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC [0-t]) of Rabeprazole812.30 ± 461.30843.68 ± 425.21
Statistical analysis
  • Idiazole 20 mg vs Pariet 20 mg · Ratio of means: 96.50 · 90% CI 90.02 to 103.44
PrimaryMean Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC [0 to Infinity]) of Rabeprazole

Blood samples were collected for pharmacokinetic analyses in each period at specified time points. Pharmacokinetic parameters of rabeprazole were estimated using standard non-compartmental methods.

Time frame:
Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2
Reported as:
Mean · Hour*nanograms per milliliter
Mean Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC [0 to Infinity]) of Rabeprazole
Hour*nanograms per milliliterIdiazole 20 mgPariet 20 mg
Mean Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC [0 to Infinity]) of Rabeprazole798.59 ± 314.16931.81 ± 442.17
Statistical analysis
  • Idiazole 20 mg vs Pariet 20 mg · Ratio of means: 95.69 · 90% CI 87.06 to 105.17
SecondaryMean Time to the Maximum Plasma Concentration (Tmax) of Rabeprazole

Blood samples were collected for pharmacokinetic analysis in each period at specified time points. Pharmacokinetic parameters of Rabeprazole were estimated using standard non-compartmental methods. Tmax was computed directly from the measured data.

Time frame:
Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2
Reported as:
Mean · Hour
Mean Time to the Maximum Plasma Concentration (Tmax) of Rabeprazole
HourIdiazole 20 mgPariet 20 mg
Mean Time to the Maximum Plasma Concentration (Tmax) of Rabeprazole3.93 ± 1.063.86 ± 1.00
SecondaryMean Apparent First-order Elimination or Terminal Rate Constant (Ke) of Rabeprazole

Blood samples were collected for pharmacokinetic analysis in each period at specified time points. Pharmacokinetic parameters of Rabeprazole were estimated using standard non-compartmental methods. Ke was derived from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations.

Time frame:
Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2
Reported as:
Mean · Per hour
Mean Apparent First-order Elimination or Terminal Rate Constant (Ke) of Rabeprazole
Per hourIdiazole 20 mgPariet 20 mg
Mean Apparent First-order Elimination or Terminal Rate Constant (Ke) of Rabeprazole0.21 ± 0.140.16 ± 0.09
SecondaryMean Terminal Half Life (t1/2) of Rabeprazole

Half life is the period of time required for the concentration or amount of drug in the body to be reduced by one-half. Blood samples were collected for pharmacokinetic analysis in each period at specified time points. Pharmacokinetic parameters of Rabeprazole were estimated using standard non-compartmental methods. t1/2 was calculated as: t1/2 = Ln(2) / (-b), where b was obtained as the slope of the linear regression of the Ln-transformed plasma concentrations versus time in the terminal period of the plasma curve.

Time frame:
Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2
Reported as:
Mean · Hour
Mean Terminal Half Life (t1/2) of Rabeprazole
HourIdiazole 20 mgPariet 20 mg
Mean Terminal Half Life (t1/2) of Rabeprazole4.49 ± 2.405.81 ± 3.08

Adverse events

Collected over From start of study treatment up to end of the follow-up (24 hours post last blood sample collected for Period 2; Up to 10 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idiazole 20 mg0/70 (0%)0/70 (0%)0/70 (0%)
Pariet 20 mg0/70 (0%)0/70 (0%)0/70 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Study Participants
Mean30.76 ± 9.05
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female25
Male45
Region of Enrollment
Region of Enrollment(Participants)All Study Participants
Egypt70
08

Study locations

1 site
  • GSK Investigational Site
    Cairo, Egypt
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Mar 2014, 0 months.

Results were first posted in Oct 2018, 4 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2015
First posted
Nov 16, 2015
StartActual
Mar 22, 2014
Primary completionActual
Mar 30, 2014
CompletionActual
Mar 30, 2014
Results first posted
Oct 1, 2018
Last update
Oct 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02605395
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 16, 2015
Start date
Mar 22, 2014
Primary completion
Mar 30, 2014
Completion
Mar 30, 2014
Results posted
Oct 1, 2018
Last update
Oct 1, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion